insiderdelta
CoverageForm 410-K10-Q8-K13D13G13F

CAH · Cardinal Health Inc - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · CAH

1Y3Y5YMax
Sign in to download
AnnualQuarterly

Income Statement

Line itemQ2 '26Q1 '26Q2 '25Q3 '25Q1 '25Q2 '24Q3 '24Q1 '24Q2 '23Q3 '23
Revenue$65.63B$64.01B$55.26B$54.88B$52.28B$57.45B$54.91B$54.76B$51.47B$50.49B
Cost of Revenue$63.23B$61.69B$53.32B$52.76B$50.38B$55.60B$52.96B$52.99B$49.81B$48.70B
Gross Profit$2.40B$2.32B$1.94B$2.12B$1.90B$1.85B$1.95B$1.77B$1.66B$1.78B
R&D----------
SG&A$1.50B$1.46B$1.31B$1.31B$1.28B$1.28B$1.28B$1.20B$1.19B$1.18B
Total Operating Expenses----------
D&A$192.00M$233.00M--$182.00M--$172.00M--
Operating Income$707.00M$668.00M$549.00M$730.00M$568.00M$482.00M$367.00M($14.00M)($119.00M)$572.00M
Interest Expense$88.00M$80.00M$35.00M$74.00M$32.00M$8.00M$33.00M$14.00M$25.00M$28.00M
Income Tax$159.00M$144.00M$110.00M$157.00M$124.00M$136.00M$82.00M($32.00M)($7.00M)$197.00M
Net Income$467.00M$450.00M$400.00M$506.00M$416.00M$353.00M$258.00M$5.00M($130.00M)$345.00M
EPS - Basic-$1.89--$1.71--$0.02--
EPS - Diluted-$1.88--$1.70--$0.02--

Balance Sheet

Line itemQ2 '26Q1 '26Q2 '25Q3 '25Q1 '25Q2 '24Q3 '24Q1 '24Q2 '23Q3 '23
Cash & Equivalents$2.78B$4.59B$3.87B$3.33B$2.87B$5.13B$3.72B$3.85B$4.04B$3.99B
Accounts Receivable$13.66B$13.77B$13.24B$12.67B$11.78B$12.08B$11.57B$11.27B$11.34B$10.99B
Inventory$20.12B$17.56B$16.83B$16.16B$15.62B$14.96B$17.28B$16.99B$15.94B$16.62B
Accounts Payable$39.00B$36.86B$34.71B$32.81B$30.36B$31.76B$32.09B$31.54B$29.81B$29.60B
Current Assets$39.23B$38.54B$36.37B$34.59B$32.91B$34.88B$35.73B$34.69B$33.83B$33.50B
Total Assets$58.08B$55.23B$53.12B$49.87B$43.06B$45.12B$45.88B$43.71B$43.42B$43.38B
Current Liabilities$43.31B$40.27B$38.90B$36.66B$34.68B$35.64B$36.31B$35.06B$33.71B$32.50B
Long-term Debt----------
Total Liabilities----------
Stockholders' Equity($2.88B)($2.88B)($2.78B)($2.95B)($3.28B)($3.21B)($3.27B)($3.49B)($2.85B)($2.22B)
Retained Earnings$1.46B$1.12B$783.00M$664.00M$14.00M($286.00M)($289.00M)($654.00M)($534.00M)($342.00M)

Cash Flow

Line itemQ2 '26Q1 '26Q2 '25Q3 '25Q1 '25Q2 '24Q3 '24Q1 '24Q2 '23Q3 '23
Operating Cash Flow-$973.00M--($1.65B)--$545.00M--
Investing Cash Flow-($142.00M)--($88.00M)--($63.00M)--
Financing Cash Flow-($110.00M)--($540.00M)--($666.00M)--
CapEx-$108.00M--$90.00M--$92.00M--
Free Cash Flow-$865.00M--($1.74B)--$453.00M--

Ratios

MetricQ2 '26Q1 '26Q2 '25Q3 '25Q1 '25Q2 '24Q3 '24Q1 '24Q2 '23Q3 '23
Profitability
Gross margin3.7%3.6%3.5%3.9%3.6%3.2%3.5%3.2%3.2%3.5%
Operating margin1.1%1.0%1.0%1.3%1.1%0.8%0.7%-0.0%-0.2%1.1%
EBITDA margin1.4%1.4%--1.4%--0.3%--
Net margin0.7%0.7%0.7%0.9%0.8%0.6%0.5%0.0%-0.3%0.7%
Free cash flow margin-1.4%---3.3%--0.8%--
FCF / Net income-1.92---4.18--90.60--
R&D / Revenue----------
SG&A / Revenue2.3%2.3%2.4%2.4%2.4%2.2%2.3%2.2%2.3%2.3%
Effective tax rate25.4%24.2%21.6%23.7%23.0%27.8%24.1%--36.3%
Return on assets0.8%0.8%0.8%1.0%1.0%0.8%0.6%0.0%-0.3%0.8%
Return on equity-16.2%-15.6%-14.4%-17.2%-12.7%-11.0%-7.9%-0.1%4.6%-15.5%
Return on invested capital----------
Liquidity
Current ratio0.910.960.940.940.950.980.980.991.001.03
Quick ratio0.440.520.500.500.500.560.510.500.530.52
Cash ratio0.060.110.100.090.080.140.100.110.120.12
Leverage
Debt / Equity----------
Debt / Assets----------
Debt / EBITDA----------
Interest coverage8.0x8.3x15.7x9.9x17.8x60.3x11.1x-1.0x-4.8x20.4x
Equity multiplier-20.14-19.18-19.10-16.92-13.14-14.04-14.05-12.52-15.22-19.54
Liabilities / Assets----------
Efficiency
Asset turnover1.131.161.041.101.211.271.201.251.191.16
Inventory turnover3.143.513.173.263.233.723.073.123.122.93
Days sales outstanding76d79d87d84d82d77d77d75d80d79d
Days inventory outstanding116d104d115d112d113d98d119d117d117d125d
Days payable outstanding225d218d238d227d220d208d221d217d218d222d
Cash conversion cycle-33d-36d-35d-31d-25d-34d-25d-25d-21d-18d
Valuation
P / E-83.5x--65.0x--4341.0x--
P / B----------
P / S0.7x0.6x0.7x0.6x0.5x0.4x0.5x0.4x0.5x0.4x
EV / EBITDA51.1x36.5x--32.3x--113.0x--
Growth
Revenue growth (YoY)18.8%22.4%-3.8%-0.1%-4.5%11.6%8.8%10.4%13.2%12.6%
Revenue CAGR (3y)8.4%8.9%6.7%7.0%5.9%11.4%11.8%11.9%9.0%8.8%
Revenue CAGR (5y)9.6%10.4%6.8%7.0%7.0%8.8%9.3%9.2%7.9%8.5%
Gross profit growth (YoY)23.5%21.9%5.1%9.0%7.6%11.0%9.1%9.5%2.9%6.1%
Operating income growth (YoY)28.8%17.6%13.9%98.9%---35.8%-87.5%-
Net income growth (YoY)16.8%8.2%13.3%96.1%8220.0%--25.2%-95.5%--
EPS growth (YoY)-10.6%--8400.0%---95.0%--
EPS CAGR (3y)-67.5%--21.8%-----
EPS CAGR (5y)-----2.6%-----
FCF growth (YoY)----------
FCF CAGR (5y)-35.1%-----8.1%--
Book value growth (YoY)-3.7%12.1%13.4%9.7%6.1%-12.7%-47.1%-96.0%-302.3%-218.5%

Sales by segment

From XBRL dimensional facts in the 10-K period ending 2025-06-30.

Business segments

$218.86B total
Pharmaceutical And Specialty Solutions$204.64B · 93.5%
GMPD$12.64B · 5.8%
All Other Segments$1.58B · 0.7%

Geographic

$222.66B total
US$220.99B · 99.3%
Non Us$1.67B · 0.7%

Peer comparison

Same SIC group: Wholesale-Drugs, Proprietaries & Druggists' Sundries

CompanyRevenue (last FY)Net marginROE
COR$321.33B0.5%103.1%
MCK$403.43B1.2%-219.2%
NUS$1.49B10.8%19.9%
HLF$5.04B4.5%-44.3%
PETQ---

Comparing CARDINAL HEALTH INC against the 5 most active filers in the same SIC group.

Dividends

$2.04/share trailing 12 months · +1.0% YoY

Ex-datePer share
Apr 1, 2026$0.5110
Jan 2, 2026$0.5110
Oct 1, 2025$0.5110
Jul 1, 2025$0.5110
Apr 1, 2025$0.5060
Jan 2, 2025$0.5060
Oct 1, 2024$0.5060
Jul 1, 2024$0.5060
Mar 28, 2024$0.5010
Dec 29, 2023$0.5010
Oct 2, 2023$0.5010
Jun 30, 2023$0.5010
Mar 31, 2023$0.4960
Dec 30, 2022$0.4960
Sep 30, 2022$0.4960
Jun 30, 2022$0.4960
Mar 31, 2022$0.4910
Dec 31, 2021$0.4910
Sep 30, 2021$0.4910
Jun 30, 2021$0.4910
Mar 31, 2021$0.4860
Dec 31, 2020$0.4860
Sep 30, 2020$0.4860
Jun 30, 2020$0.4860